Abivax S.A. Stock
Abivax S.A. Stock
There is an upward development for Abivax S.A. compared to yesterday, with an increase of €2.20 (2.050%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Abivax S.A. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Abivax S.A. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Abivax S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Abivax S.A. | 2.050% | - | - | - | - | - | - |
| Nanobiotix | 0.300% | -4.395% | -3.067% | 484.642% | 75.393% | 404.518% | 187.554% |
| Innate Pharma | 3.310% | -5.224% | -7.524% | -15.987% | -0.392% | -42.382% | -44.257% |
| Poxel S.A. | -0.240% | 3.579% | 3.579% | -60.481% | -14.017% | -65.807% | -96.561% |
Comments
DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu
DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.News
EQS-News: Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
EQS-News: Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
EQS-News: Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
EQS-News: Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
EQS-News: Abivax Announces Closing of $920 Million Public Offering
EQS-News: Abivax Announces Closing of $920 Million Public Offering